Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03475966
Other study ID # prehab_pilot
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 22, 2017
Est. completion date June 30, 2022

Study information

Verified date December 2020
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Antonio Vigano, MD, MSc
Phone 514-934-1934
Email antonio.vigano@mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Major surgery is a stressful procedure; good recovery after surgery is important to patients and their doctors. Studies done at the McGill University Health Centre (MUHC) with cancer patients awaiting surgery have shown that exercise combined with simple diet recommendations (which may include a supplement) and relaxation techniques before surgery helped speed up the ability to resume walking after surgery. These results have made the investigators aware that exercise and good nutrition are as important before surgery as they are after surgery; while it is common practice to start strengthening the body after surgery (rehabilitation), there may be some advantage to begin this process before surgery (prehabilitation). The purpose of this study is to see if the following program, either before or after surgery, can help patients recover from liver, pancreas or bile duct surgery: 1. Exercise that may help participants move and breath better, 2. Nutrition advice and a supplement to make participants strong, 3. Relaxation and anti-anxiety tips to help cope with the stress of upcoming surgery The investigators will see if following this program will have an effect on participants' ability to walk before and after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 95 Years
Eligibility Inclusion criteria: - A diagnosis or suspicion of either hepatobiliary or pancreatic cancer (primary or metastatic) - Must be scheduled for surgical resection between 4-6 weeks of recruitment Exclusion criteria: - Persons with American Society of Anesthesiologists (ASA) health status class 4-5 - Comorbid medical, physical and mental conditions (eg: dementia, disabling orthopedic and neuromuscular disease, psychosis) - Cardiac abnormalities - Severe end-organ disease such as cardiac failure, chronic obstructive pulmonary failure and hepatic failure (alanine aminotransferase and aspartate aminotransferase >50% over the normal range) - Sepsis - Morbid obesity (BMI >40) - Anemia (hematocrit <30 %) - Other conditions interfering with the ability to perform exercise at home or to complete the testing procedures - Poor English or French comprehension

Study Design


Intervention

Other:
Exercise
A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
Nutrition
Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
Behavioral:
Relaxation techniques
Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.

Locations

Country Name City State
Canada McGill University Health Centre Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre Dr. Franco Carli

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Lower extremity strength - assessment of change over time Optional measure: assessed using the Biodex System 3 (Biodex Medical Systems, Shirley, NY). Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Primary Change in functional walking capacity as measured by the six-minute walk test (6MWT) The 6MWT evaluates the ability of an individual to maintain a moderate level of physical activity over a time period reflective of the activities of daily living. Subjects are instructed to walk back and forth, in a 20 meter stretch of hallway, for six minutes, at a pace that would make them tired by the end of the walk; encouragement and feedback are given according to published guidelines. They are allowed to rest during the test if needed, but this time is included in the 6 minutes. Reference equations are available for calculating percent of age- and gender-specific norm. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Timed up and go test Investigators will measure the time required for a participant to stand up from being seated, walk a distance of 3 metres, turn around and walk back to the chair, and sit down. This measure will be administered based on Canadian Society for Exercise Physiology standards. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary 30-second sit to stand test Investigators will measure the number of times participants can stand from a seated position in 30-seconds. This measure will be administered based on Canadian Society for Exercise Physiology standards. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary 30-second arm curl test Investigators will measure the number of times participants can perform a full arm curl in 30-seconds. Both arms will be assessed, one at a time. This measure will be administered based on Canadian Society for Exercise Physiology standards. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Change in handgrip strength To be measured using the Jamar hydraulic hand dynamometer. Two measures from each hand will be taken, with patient seated and arm bent at a 90-degree angle. The average of the two measures for each hand will be recorded and compared to normative data. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Change in body composition Body composition will be measured via dual-energy X-ray absorptiometry (DXA; Lunar Prodigy Advance, General Electric Healthcare, Madison, WI). Studies from the McGill Nutrition and Performance Laboratory group have validated the use of DXA in advanced cancer patients. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Assessment of food intake and change over study period Participants will be asked to bring a 3-day food diary to their baseline visit to obtain detailed information about the quantity and type of food and beverages consumed during a non-consecutive 3-day period. Overall energy intake, as well as macronutrient distribution (e.g., amount of carbohydrates, fats, proteins, and fibre at each meal) will be calculated using the Food Processor SQL Nutrition Analysis software. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Perioperative data This data will include operative characteristics, transfusion rates, length of surgery, intraoperative complications and length of stay. 7 days post-operatively
Secondary Postoperative complications Including surgical site infection, other infectious complications (such as pneumonia, urinary tract infection, line sepsis), bile leak, hemorrhage, deep vein thrombosis, etc., will be recorded and scored using the Clavien Classification. 4 weeks post-operatively
Secondary Health-related quality of life (HRQL) - assessment of change over time As measured by the acute (1 week recall period) Functional Assessment of Cancer Therapy (FACT) survey. This questionnaire also has versions that identify symptoms more specific to hepatobiliary and colorectal cancer patients; this is of relevance to this study given liver metastasis occurs in these patients. The questionnaire is separated into five subscales: 1) physical well-being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, 5) additional concerns (specific to cancer type). Each question is scored 0-4 on a likert scale, with 0 indicating, "not at all," and 4 indicating, "very much." These scores are then reversed where applicable and added. A higher score indicates better QoL. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary The Edmonton Symptom Assessment System (ESAS) - assessment of change over time Currently used at the MUHC Cedars Cancer Centre to assist in the assessment of pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath. Each symptom is rated from 0 to 10 on a numerical scale based on severity, with 0 indicating that the symptom is absent and 10 that it is the worst possible severity. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Physical activity level - assessment of change over time Will be measured through the Community Health Activities Model Program for Seniors (CHAMPS) questionnaire. The CHAMPS is a self-reported measure of physical activity, comprising 41 activities evaluated according to the total number of hours done during an average week. Each physical activity is assigned a metabolic equivalent (MET) value yielding average weekly caloric expenditure for the listed physical activities. There is evidence for the validity of CHAMPS as a measure of postoperative recovery. Data will be categorized as either mild, moderate or intense activity and changes in the number of hours spent performing activities within each category will be assessed. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Nutritional status - assessment of change over time To be assessed using the Abridged Patient-Generated Subjective Global Assessment (aPG-SGA); a validated questionnaire used to assess the nutritional and functional status of cancer patients. The scoring system allows patients at risk for malnutrition to be identified and triaged for nutritional intervention. The aPG-SGA may also be useful in monitoring short-term changes in nutritional status. A score =9 indicates a critical need for nutritional intervention. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Fatigue - assessment of change over time To be assessed using a visual analog scale (1-10) and the Brief Fatigue Inventory (BFI). The BFI assesses the level of fatigue and its impact on activities of daily living. The test has 9 questions: three questions are designed to assess the patient's fatigue during the immediate waking hours and 6 questions address how fatigue has interfered in the patient's life over the previous 24 hours. Each question uses a scale rating from "0" (no fatigue) to "10" (unimaginable fatigue) for a total of 90 points. Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Weight - assessment of change over time Body weight will be measured (Kg) Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Height Height will be measured with a stadiometer (m) Baseline
Secondary Body mass index - assessment of change over time Calculated wt (kg)/ht^2 (m) Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Blood pressure - assessment of change over time Systolic and diastolic at rest (mmHg) Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
Secondary Heart rate - assessment of change over time Beats per minute measured using a pulse oximeter Baseline, pre-operative assessment, 4 weeks post-operative, 8 weeks post-operative
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study